Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The inactivated poliovirus antigen is the immunogenic component of the inactivated polio vaccine (IPV). It comprises whole poliovirus particles, typically inactivated by formaldehyde, retaining their ability to induce a protective immune response. The antigen is derived from one or more of the three poliovirus serotypes (types 1, 2, and 3). The inactivation process can modify or destroy certain epitopes, especially those at site 1 on types 2 and 3, leading to reduced binding by some monoclonal antibodies. IPV induces a strong humoral immune response characterized by production of neutralizing antibodies. Immunogenicity can vary depending on whether wild-type or attenuated Sabin strains are used.
Induction of neutralizing antibodies against poliovirus serotypes 1, 2, and 3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Antigen (Inactivated) (IPV Antigen).